MINDMAZE THERAPEUTICS HOLDING SAMMTX
▲ PositiveTechnologyrelevance
MindMaze announced MindMotion Lite, a tablet-based home neurorehabilitation product, expanding its product offering.
Impact on stocks 3
Brain-Computer Interface▲ · 1 stocks
MINDMAZE THERAPEUTICS HOLDING SAFinancials▲ · 1 stocks
Others▲ · 1 stocks
Bank of Chongqing Co Ltd601963
Mentioned
Theme Impact 1
Off-coverage companies
Related news
▼2
BrightSpring Sees $200M IRA Revenue Hit to Home and Community Pharmacy
BrightSpring Health Services' Home and Community Pharmacy segment expects the Inflation Reduction Act to cut its full-year 2026 revenues by approximately $200 million, even as the company holds its estimated EBITDA impact to roughly $15 million. In the second quarter, segment revenues fell 8% year over year to $540 million, with management attributing part of the decline to an approximately $50 million IRA impact during the quarter alongside the exit from certain uneconomic customers. Home and Community Pharmacy EBITDA still increased year over year in the second quarter, which management credited to operational process enhancements and the deployment of new technologies, with technology, automation and AI, Lean initiatives and procurement improvements central to that efficiency strategy. BrightSpring estimates the 2027 IRA impact on the segment will be roughly 50% of the 2026 impact, while it pursues regulatory, payer-contracting and operational measures to mitigate the pressure. Among peers, Cardinal Health has entered fiscal 2027 facing an estimated 500-basis-point Pharma revenue headwind from IRA pricing changes but expects little to no profit impact, while CVS Health reported Pharmacy & Consumer Wellness revenue pressure from regulatory price reductions even as adjusted operating income rose more than 10% year over year.
Survey Finds 70% of Gen Z US Healthcare Workers Plan to Job Hunt Within a Year
About 70% of Generation Z healthcare workers in the United States expect to explore new roles over the next year, according to a survey released on Wednesday by Harris Poll, commissioned by education services company Strategic Education and Workforce Edge. The findings point to a retention challenge for U.S. healthcare employers already facing a projected shortage of nearly 500,000 workers by 2038. Yet 65% of Gen Z respondents said they ultimately hope to remain with one employer for five years or more, and nearly all said job stability was important to them. Across all age groups, 59% of healthcare workers said they expect to seek a new role over the next year. The survey, conducted online from June 12 to July 1, covered 1,514 healthcare employees and 304 employers, and found that nearly half of employers cited a lack of career growth or training as the top reason workers leave, while only about one in four employees trusted their employer to invest in their future. Employers also appear to be reassessing artificial intelligence in workforce planning, with about 79% saying AI skills would be critical for employees to remain competitive, down from 89% a year earlier.
▲
BrightSpring Health Services Sees 2026 Earnings Estimate Rise to $1.82 Per Share
Zacks Investment Research has raised its 2026 consensus earnings estimate for BrightSpring Health Services by 16 cents to $1.82 per share, implying 82% growth over the prior-year reported level, while the 2026 revenue consensus stands at $15.26 billion, an 18.2% improvement. The Louisville, Kentucky-based home and community-based healthcare platform, which carries a Zacks Rank #1 (Strong Buy) and an $11.62 billion market capitalization, is banking on expanding specialty pharmacy beyond oncology, infusion growth into another 12 to 15 states over the next five years, and deeper payer and hospital system relationships in Provider Services. BrightSpring shares have rallied 61% year to date, against a 3.2% gain for the industry and an 11.1% rise for the S&P 500, leaving its forward P/E of 32.35 well above the industry average of 16.92. Management expects the 2027 Inflation Reduction Act impact on Home and Community Pharmacy to be roughly half of the 2026 impact, though Specialty Pharmacy will continue to face revenue pressure, and integration of Amedisys and LHC plus automation and AI investments carry execution risk through 2026.